Lower Extremity Spasticity: Causes, Symptoms, and Treatment

Lower extremity spasticity is involuntary muscle stiffness and tightness in the legs that develops after damage to the brain or spinal cord, most commonly from stroke, multiple sclerosis, cerebral palsy, or spinal cord injury. The muscles resist being stretched, often leaving the leg in a rigid or awkward position that makes walking difficult or impossible. Because the condition arises from disrupted communication between the brain and the spinal cord rather than a problem in the muscles themselves, treating it requires addressing both the overactive nerve signals and their downstream consequences in the limbs.

Why the Legs Become Stiff After a Neurological Injury

Your brain constantly sends signals down the spinal cord to regulate muscle tone, balancing excitatory messages that activate muscles with inhibitory ones that keep them relaxed. When a stroke, traumatic brain injury, or spinal cord lesion damages the pathways carrying those signals, the inhibitory input drops off while excitatory signals persist or even increase. The result is a spinal cord that overreacts to normal sensory input from the muscles, producing exaggerated stretch reflexes and sustained tightness.

Current models point to injury in the corticospinal and corticoreticulospinal tracts, altered drive from the brainstem, amplified spinal reflexes, and impaired inhibitory control as central contributors. Over time, the muscles and connective tissue themselves undergo secondary changes that add a mechanical component to the stiffness.¹ An important clue about the process is its timing: spasticity rarely appears immediately after a stroke or injury. The delay suggests that the spinal cord undergoes gradual plastic changes once it loses its usual regulation from the brain. One such change is a progressive reduction in a dampening mechanism called postactivation depression, which may be worsened by the simple fact that an immobilized limb is not being moved through its normal range of motion.²

Research also implicates the brain’s inhibitory neurotransmitter GABA. After a spinal cord injury, there may be a brief flood of GABA that contributes to the initial “spinal shock” phase of floppiness, followed by a longer-term deficit in GABAergic signaling that tips the balance toward overexcitable motor neurons and spasticity.³ This understanding is directly relevant to treatment, because the most commonly prescribed oral medications for spasticity work by boosting GABA activity in the spinal cord.

The Underlying Conditions

Lower extremity spasticity is not a disease on its own. It is a downstream consequence of a neurological condition that damages upper motor neurons. The most frequent causes include stroke, spinal cord injury, multiple sclerosis, cerebral palsy, and traumatic brain injury.⁴ Each condition creates a somewhat different pattern. Stroke tends to affect one side of the body, producing spasticity in one leg more than the other. Spinal cord injuries can produce bilateral spasticity in both legs depending on the level and completeness of the lesion. Multiple sclerosis, because it involves scattered areas of damage, can cause spasticity that fluctuates over time and may worsen during flare-ups. In cerebral palsy, the injury occurs before, during, or shortly after birth, meaning the growing child develops motor patterns around the spasticity from the start.

The specific pattern matters because it shapes both the symptoms a person experiences and the treatment strategy that makes sense. A person with post-stroke spasticity affecting one leg has different rehabilitation goals and injection targets than a child with cerebral palsy who has stiffness in both legs.

What Lower Extremity Spasticity Feels and Looks Like

The hallmark of spasticity is velocity-dependent resistance to passive stretch. If someone moves your leg slowly, the muscles may feel fairly normal. But move it quickly and they lock up, resisting the movement with increasing force. This distinguishes spasticity from simple stiffness or rigidity, which tends to feel the same regardless of speed.⁵

In the legs, the most common patterns include:

Equinus foot: The calf muscles pull the foot downward and inward so that the toe points down, making it difficult to place the heel on the ground during walking.
Stiff knee: The quadriceps stay contracted through the swing phase of gait, preventing the knee from bending enough to clear the foot off the ground.
Adducted thighs: The inner thigh muscles pull the legs together, sometimes causing a scissoring pattern during walking.
Flexed hip: The hip flexors remain tight, making it hard to stand fully upright.

These patterns often coexist. In children with cerebral palsy, gait analysis has identified recognizable combinations such as “jump gait,” where the child walks on the toes with the hips and knees flexed, and “crouch gait,” where excessive bending at the hips, knees, and ankles produces a crouched posture. However, gait patterns in cerebral palsy tend to exist along a continuum rather than in sharply defined categories, and the visible walking pattern is always a mix of the primary spasticity and the compensatory strategies the person develops to work around it.⁶

A related phenomenon is clonus, a rhythmic, involuntary jerking of the foot or knee that happens when the muscle is stretched. Like spasticity, clonus results from an upper motor neuron lesion that removes normal inhibition of spinal reflexes, but instead of sustained stiffness the reflex fires in rapid, repetitive bursts.⁵ People with lower extremity spasticity frequently report clonus in the ankle, where a sudden stretch of the calf (like pushing the foot upward) triggers a series of involuntary downward beats that can last seconds or longer.

Beyond the visible tightness and abnormal postures, spasticity often brings pain, difficulty sleeping, skin breakdown from sustained pressure of a flexed limb, and fatigue from the effort of fighting rigid muscles during everyday activities.

How Clinicians Measure Spasticity

There is no blood test or imaging scan that quantifies spasticity. Clinicians rely on bedside scales in which they passively move a limb and rate how much the muscles resist. The two most widely used are the Modified Ashworth Scale and the Modified Tardieu Scale. They look similar from the outside, but they measure subtly different things. The Ashworth scale rates the overall resistance felt during passive movement without distinguishing whether that resistance is coming from overactive reflexes or from physical changes in the muscle and connective tissue. The Tardieu scale tries to isolate the neural component by comparing the muscle’s response at slow and fast stretch speeds.

Research comparing the two scales in the lower limbs has found that they do not always agree. The Modified Ashworth Scale tends to classify spasticity as present more often than the Tardieu Scale, and agreement between the two depends heavily on which muscle is being tested. For the hamstrings at certain hip positions, agreement has been reported as low as about 18%, while for the gastrocnemius (calf muscle) it was closer to 78%.⁷ Studies in children with cerebral palsy have similarly found that while the two scales correlate moderately, they are measuring related but distinct aspects of the stiffness, so they are not interchangeable.⁸

For the person living with leg spasticity, the practical takeaway is that the number on a clinical scale does not always correspond neatly to how much the spasticity affects daily life. Two people with the same Ashworth score can have very different walking abilities, pain levels, and functional limitations. That is why treatment decisions increasingly rely on goal-oriented assessments rather than scale scores alone, asking what specific activity the person wants to improve rather than simply aiming to lower a number.

Oral Medications

When spasticity needs to be managed across the whole body or affects large muscle groups, oral medications are usually the first-line approach. The three most established options are baclofen, tizanidine, and dantrolene. Systematic review evidence rates all three as effective compared to placebo for reducing spasticity, with the strongest evidence base in people with multiple sclerosis. Baclofen and tizanidine appear roughly equivalent in overall efficacy, though their side-effect profiles differ: tizanidine is more likely to cause dry mouth, while baclofen more often causes muscle weakness.⁹

Baclofen works by activating GABA-B receptors in the spinal cord, essentially reinforcing the inhibitory signaling that the neurological injury has reduced. Tizanidine takes a different route, acting on alpha-2 adrenergic receptors to quiet down excitatory nerve activity in the spinal cord. Dantrolene is the outlier: it acts directly on muscle fibers rather than on the nervous system, reducing the release of calcium needed for contraction. This gives it a distinct role for people who cannot tolerate central nervous system side effects like drowsiness, but it carries a risk of rare serious liver toxicity that requires monitoring.⁹

A common frustration with oral medications is that they are systemic: they reduce tone in all muscles, not just the problematic ones. For someone whose main issue is a stiff calf pulling the foot down, weakening the quadriceps and hip flexors along with the calf can make walking worse overall despite improving flexibility in the target muscle. This trade-off is the main reason clinicians look to more targeted interventions when leg spasticity is focal or when oral drugs produce excessive sedation or weakness.

Botulinum Toxin Injections

Botulinum toxin, the same substance used in cosmetic procedures, has become a cornerstone of focal spasticity treatment. Injected directly into the overactive muscle, it blocks the release of the neurotransmitter acetylcholine at the nerve-muscle junction, producing a temporary chemical weakening of that specific muscle. The effect on the muscle spindles that drive the stretch reflex peaks around two weeks after injection and gradually wears off over roughly twelve weeks.¹⁰

For lower limb spasticity, expert consensus has identified targeted muscle subsets for common postures like equinus foot and stiff knee. Doses for individual muscles in the leg typically range from 20 to 150 units, with total doses for a given limb posture ranging from 50 to 300 units. The toxin is typically diluted to a concentration of 50 units per milliliter for leg muscles, though the dilution may vary depending on the target. Clinicians use localization techniques such as ultrasound or electrical stimulation to make sure the needle is placed in the right muscle belly.¹¹

The appeal of botulinum toxin for leg spasticity is its precision. Rather than dampening muscle activity body-wide, you can selectively relax the calf while leaving the quadriceps and hip muscles at full strength, which can improve walking efficiency in a way that oral medications alone cannot. The downside is the need for repeated injections every three to four months and the risk of developing antibodies over time, which can make subsequent injections less effective. Botulinum toxin is also most useful when one or a few muscles are the primary problem; when spasticity is widespread across many muscle groups in both legs, the injectable volumes needed start to push against safety limits.

Intrathecal Baclofen Pumps

For people with severe spasticity in both legs that has not responded adequately to oral medications, an intrathecal baclofen pump offers a way to deliver the drug directly to the spinal fluid surrounding the spinal cord. Because the medication reaches its target without passing through the bloodstream, it can achieve much higher local concentrations at a fraction of the oral dose, dramatically reducing the sedation and systemic weakness that limit oral baclofen.

Candidates are typically those with intractable spasticity uncontrolled by oral drug therapy or who experience intolerable side effects from oral baclofen. Before a permanent pump is implanted, clinicians perform a trial injection of baclofen into the spinal fluid to confirm that the patient responds. Evidence supports the pump’s effectiveness for both short-term and long-term reduction of severe spasticity.¹² In one study of patients with severe spastic paraplegia who had failed combination oral therapy, all started at the highest severity grade. Under intrathecal baclofen, roughly 40% improved to near-normal tone and another 60% improved to a moderate level.¹³

A lingering concern among patients and clinicians alike has been whether intrathecal baclofen might weaken the legs enough to compromise walking in people who are still ambulatory. A study in people with multiple sclerosis found that 75% of those who received a pump remained ambulatory over an average follow-up of nearly four years. After implantation, 85% were able to discontinue all oral anti-spasticity medications, eliminating the systemic side effects those drugs were causing.¹⁴ The takeaway from that work is that, with careful patient selection, the pump should not be considered a last resort reserved only for wheelchair-bound patients. It can be introduced earlier in the treatment course, particularly when oral drugs are causing problems.

The pump does require surgical implantation under the skin of the abdomen, with a catheter threaded into the spinal canal. It needs refilling every one to six months, depending on the dose, and the device itself is replaced surgically every five to seven years. Complications include catheter kinks or disconnections, infection, and the risk of baclofen withdrawal (which can be life-threatening) if the pump malfunctions or runs empty.

Rehabilitation, Electrical Stimulation, and Orthoses

Medications and injections reduce muscle tone, but they do not retrain the nervous system or rebuild strength. Physical therapy is the connective tissue that holds a spasticity management plan together. Stretching programs, strengthening exercises, task-specific gait training, and positioning strategies all play roles, typically beginning soon after the neurological event and continuing long term.

Electrical stimulation is sometimes used as an adjunct. Both transcutaneous electrical nerve stimulation (TENS) and functional electrical stimulation (FES) have shown anti-spasticity effects in the lower limbs of people with spinal cord injuries. A pilot crossover trial comparing the two found that both produced meaningful reductions in spasticity scores lasting up to about four hours after a single session.¹⁵ The effects are temporary, which means electrical stimulation is most useful as a window of reduced tone during which a person can more easily engage in active exercise or gait training.

Ankle-foot orthoses and other lower limb braces serve a different but complementary purpose. They hold the foot and ankle in a functional position, preventing the spastic calf from pulling the foot into equinus during walking and providing stability at the knee. In children with cerebral palsy, lower limb orthoses are a standard part of the rehabilitation toolkit, with a large body of research examining their effects on gait patterns. Orthotic prescription can be complex, however, because the brace needs to balance support against the goal of encouraging active muscle use.

Selective Dorsal Rhizotomy

When spasticity in the legs is severe and other treatments have not achieved adequate control, surgery enters the conversation. The most established surgical procedure specifically targeting lower limb spasticity is selective dorsal rhizotomy, in which a neurosurgeon selectively cuts sensory nerve rootlets entering the spinal cord. By interrupting the overactive sensory feedback loop that drives the exaggerated stretch reflex, the procedure permanently reduces spasticity in the affected muscles.¹⁶

The procedure is most commonly performed in children with cerebral palsy, typically between ages 3 and 8, when the child has spasticity as the dominant motor problem and has enough underlying strength to benefit from the reduction in tone. It is a one-time intervention, unlike botulinum toxin injections that must be repeated. However, it is irreversible, and it must be followed by intensive physiotherapy, often lasting a year or more, to build the strength and motor skills that the previously overwhelming spasticity was masking.

For adults, selective dorsal rhizotomy is less commonly offered, though interest has grown in recent years for adults with cerebral palsy who were not treated surgically as children. Patient selection is critical: the surgery reduces spasticity, but it does not address weakness, coordination problems, or fixed contractures. If a person’s functional limitations come mainly from weakness rather than tone, removing the spasticity may actually make things worse by eliminating muscle stiffness that was inadvertently helping them stand or walk.

Robotic-Assisted Gait Training

A newer addition to the rehabilitation toolkit is robotic-assisted gait training, in which a powered exoskeleton supports the patient’s legs and guides them through a normal walking pattern on a treadmill or over ground. The premise is that repeated, high-volume, consistent stepping may help the nervous system relearn motor patterns more effectively than manual-assisted walking alone. Early evidence in stroke patients is encouraging. A study of 19 stroke patients using a lower extremity exoskeleton found improvements in both gait measures and functional status, with the intervention being well tolerated.¹⁷

Robotic gait training is still relatively expensive and not widely available outside major rehabilitation centers. Its role in routine spasticity management remains unsettled. Still, as the technology matures and costs come down, it is likely to play a growing part in the rehabilitation of people with lower limb spasticity, particularly for those too weak to practice walking without substantial physical support.

The Multidisciplinary Clinic Model

Spasticity in the legs rarely responds well to a single treatment delivered in isolation. Increasingly, specialized multidisciplinary spasticity clinics bring together neurologists, rehabilitation physicians, physiotherapists, orthotists, and sometimes neurosurgeons to coordinate care. A recent pragmatic study of one such lower limb spasticity clinic found that after individualized treatment protocols, patients showed significant improvements in gait speed, dynamic balance, and lower limb function. Quality of life also improved, though that improvement did not reach statistical significance. Over 85% of participants reported satisfaction with the service, and orthotic wait times dropped substantially, with roughly half of patients assessed and fitted within two weeks.¹⁸

The functional gains matter because they translate directly into daily life. A meaningful improvement in gait speed can mean the difference between needing a wheelchair for community outings and being able to walk short distances independently. Dynamic balance improvements reduce fall risk. And streamlining the process of getting an orthotic device means less time spent struggling without proper support.

When Spasticity Is Actually Useful

One counterintuitive reality that surprises many patients and families is that some degree of lower extremity spasticity can be functionally helpful. A person with very weak leg muscles after a spinal cord injury or stroke may rely on the stiffness in their quadriceps to keep the knee from buckling during standing. Remove that tone entirely and the leg collapses. Calf spasticity, while it pulls the foot into an awkward position, can sometimes provide enough rigidity to bear weight during transfers from a wheelchair.

This is why experienced clinicians talk about managing spasticity rather than eliminating it. The goal is to reduce tone enough to relieve pain, improve function, and prevent complications like contractures, while preserving any useful stiffness that the person has learned to exploit. Treatment is not about chasing a normal-feeling limb at all costs. It is about finding the level of tone that gives a particular person the best combination of comfort, function, and quality of life, and that target varies enormously from one individual to the next. Setting individualized, functional goals before starting treatment is what separates an effective spasticity management plan from one that looks good on a clinical scale but leaves the person worse off in practice.